 ESSA Pharma developed a novel mode of action drug, EPI-7386, for the treatment of metastatic castrate-resistant prostate cancer. Pre-clinical and early Ph 1 results are promising. ESSAs share price crashed in mid-Aug when a change in the Ph 1 trial protocol was announced, and a delay in the expected Ph 1 monotherapy trial data release. I believe the market overreacted. 